Catalio Capital Management
Latest statistics and disclosures from Catalio Capital Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are GILD, BMY, BSX, BBOT, LLY, and represent 29.00% of Catalio Capital Management's stock portfolio.
- Added to shares of these 10 stocks: GILD (+$36M), BMY (+$35M), BBOT (+$31M), JNJ (+$25M), EW (+$16M), MLYS (+$12M), ACLX (+$10M), DYN (+$10M), BSX (+$9.3M), OCUL (+$8.7M).
- Started 14 new stock positions in BLLN, ACLX, MLYS, FULC, JNJ, TERN, HTFL, BBOT, BMY, DYN. OLMA, GILD, OCUL, EW.
- Reduced shares in these 10 stocks: , LLY (-$34M), BBIO (-$32M), GPCR (-$28M), ISRG (-$25M), NTRA (-$20M), , CYTK (-$12M), RNA (-$12M), GRAL (-$9.2M).
- Sold out of its positions in ABBV, RNA, BBIO, CDTX, EXAS, KYTX, MLTX.
- Catalio Capital Management was a net seller of stock by $-70M.
- Catalio Capital Management has $566M in assets under management (AUM), dropping by 4.60%.
- Central Index Key (CIK): 0001958125
Tip: Access up to 7 years of quarterly data
Positions held by Catalio Capital Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Catalio Capital Management
Catalio Capital Management holds 45 positions in its portfolio as reported in the December 2025 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Gilead Sciences (GILD) | 6.3 | $36M | NEW | 289k | 122.74 |
|
| Bristol Myers Squibb (BMY) | 6.2 | $35M | NEW | 648k | 53.94 |
|
| Boston Scientific Corporation (BSX) | 6.1 | $34M | +37% | 360k | 95.35 |
|
| Bridgebio Oncology Therapeut Com New (BBOT) | 5.6 | $31M | NEW | 411k | 76.49 |
|
| Eli Lilly & Co. (LLY) | 4.9 | $28M | -54% | 26k | 1074.68 |
|
| Dianthus Therapeutics (DNTH) | 4.8 | $27M | -2% | 654k | 41.21 |
|
| Ascendis Pharma A/s Sponsored Adr (ASND) | 4.5 | $25M | -17% | 119k | 213.24 |
|
| Syndax Pharmaceuticals (SNDX) | 4.4 | $25M | -25% | 1.2M | 21.01 |
|
| Johnson & Johnson (JNJ) | 4.4 | $25M | NEW | 121k | 206.95 |
|
| Regeneron Pharmaceuticals (REGN) | 4.1 | $23M | -15% | 30k | 771.87 |
|
| Structure Therapeutics Sponsored Ads (GPCR) | 3.1 | $18M | -61% | 253k | 69.55 |
|
| Soleno Therapeutics (SLNO) | 2.9 | $17M | -13% | 360k | 46.30 |
|
| Cytokinetics Com New (CYTK) | 2.9 | $16M | -42% | 258k | 63.54 |
|
| Edwards Lifesciences (EW) | 2.8 | $16M | NEW | 187k | 85.25 |
|
| Intuitive Surgical Com New (ISRG) | 2.7 | $15M | -61% | 27k | 566.36 |
|
| Natera (NTRA) | 2.5 | $14M | -58% | 62k | 229.09 |
|
| Adaptive Biotechnologies Cor (ADPT) | 2.4 | $13M | -7% | 821k | 16.24 |
|
| Abivax Sa Sponsored Ads (ABVX) | 2.3 | $13M | -39% | 99k | 134.85 |
|
| Supernus Pharmaceuticals (SUPN) | 2.3 | $13M | -10% | 258k | 49.70 |
|
| Fractyl Health (GUTS) | 2.1 | $12M | +5% | 5.5M | 2.20 |
|
| Mineralys Therapeutics (MLYS) | 2.1 | $12M | NEW | 332k | 36.29 |
|
| Phathom Pharmaceuticals (PHAT) | 2.0 | $12M | -38% | 699k | 16.59 |
|
| Adma Biologics (ADMA) | 1.8 | $10M | -17% | 565k | 18.24 |
|
| Arcellx Common Stock (ACLX) | 1.8 | $10M | NEW | 156k | 65.20 |
|
| Dyne Therapeutics (DYN) | 1.8 | $10M | NEW | 520k | 19.56 |
|
| Disc Medicine (IRON) | 1.5 | $8.8M | -49% | 110k | 79.41 |
|
| Ocular Therapeutix (OCUL) | 1.5 | $8.7M | NEW | 715k | 12.14 |
|
| Septerna (SEPN) | 1.5 | $8.2M | 294k | 27.88 |
|
|
| Protara Therapeutics Com Stk (TARA) | 1.4 | $7.7M | -3% | 1.4M | 5.33 |
|
| Uniqure Nv SHS (QURE) | 1.2 | $6.9M | 288k | 23.93 |
|
|
| Olema Pharmaceuticals (OLMA) | 1.2 | $6.7M | NEW | 267k | 25.00 |
|
| Terns Pharmaceuticals (TERN) | 1.0 | $5.5M | NEW | 137k | 40.40 |
|
| Ultragenyx Pharmaceutical (RARE) | 0.7 | $3.7M | -44% | 163k | 23.00 |
|
| Heartflow Inc/Sh (HTFL) | 0.6 | $3.3M | NEW | 114k | 29.15 |
|
| Grail (GRAL) | 0.5 | $2.6M | -78% | 30k | 85.59 |
|
| Fulcrum Therapeutics (FULC) | 0.4 | $2.3M | NEW | 201k | 11.31 |
|
| Billiontoone Cl A (BLLN) | 0.4 | $2.1M | NEW | 26k | 81.84 |
|
| Eledon Pharmaceuticals (ELDN) | 0.3 | $1.9M | +18% | 1.3M | 1.51 |
|
| Hyperfine Com Cl A (HYPR) | 0.2 | $1.3M | +92% | 1.3M | 0.98 |
|
| Palvella Therapeutics Inc Ne (PVLA) | 0.2 | $1.1M | -12% | 11k | 104.67 |
|
| Karyopharm Therapeutics Com New (KPTI) | 0.2 | $1.1M | 143k | 7.36 |
|
|
| Metagenomi (MGX) | 0.2 | $857k | 529k | 1.62 |
|
|
| Atai Beckley Nv SHS | 0.1 | $805k | 197k | 4.09 |
|
|
| Outset Med Com New (OM) | 0.1 | $439k | 118k | 3.71 |
|
|
| Sensei Biotherapeutics Com New (SNSE) | 0.0 | $157k | 15k | 10.67 |
|
Past Filings by Catalio Capital Management
SEC 13F filings are viewable for Catalio Capital Management going back to 2025
- Catalio Capital Management 2025 Q4 filed Feb. 17, 2026
- Catalio Capital Management 2025 Q3 filed Nov. 14, 2025